Oppenheimer Holdings, Inc. restated their hold rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report published on Wednesday morning.

A number of other research analysts also recently issued reports on TEVA. Jefferies Group LLC restated a hold rating and set a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. ValuEngine upgraded Teva Pharmaceutical Industries Limited from a hold rating to a buy rating in a research note on Monday. Mizuho restated a hold rating and set a $16.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Deutsche Bank AG restated a buy rating and set a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Sanford C. Bernstein downgraded Teva Pharmaceutical Industries Limited from an outperform rating to a market perform rating and dropped their price target for the stock from $42.00 to $28.00 in a research note on Friday, August 4th. Five research analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has an average rating of Hold and a consensus target price of $29.39.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 2.49% during midday trading on Wednesday, reaching $15.68. The company’s stock had a trading volume of 37,567,439 shares. The stock’s 50-day moving average price is $16.99 and its 200-day moving average price is $26.97. The company’s market cap is $15.93 billion. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $45.85. Teva Pharmaceutical Industries Limited also was the recipient of unusually large options trading on Wednesday. Stock traders purchased 29,656 put options on the company. This represents an increase of approximately 231% compared to the average volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.25 EPS. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Receives Hold Rating from Oppenheimer Holdings, Inc.” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/05/teva-pharmaceutical-industries-limited-teva-receives-hold-rating-from-oppenheimer-holdings-inc-2.html.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were given a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 2.17%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

A number of institutional investors have recently added to or reduced their stakes in TEVA. San Francisco Sentry Investment Group CA purchased a new position in Teva Pharmaceutical Industries Limited during the second quarter worth $106,000. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC purchased a new position in Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. increased its position in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares in the last quarter. 56.77% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.